A new drug being developed by Roche to treat Alzheimer's has found some success in a small clinical trial after a new report published in the Archive of Neurology revealed that it was able to remove amyloid plaques from the brains of Alzheimer's disease patients.
The study was led by Dr Susanne Ostrowitzki in Switzerland and included 16 patients suffering from Alzheimer's. The researchers divided the patients into two groups, and each group was given two to seven infusions of intravenous gantenerumab of 60 mg or 200 mg strengths or placebo every four weeks.
The researchers found that gantenerumab was successfully able to remove amyloid plaques and slow down the progression of the disease when the patients were still functional. "Our study demonstrates that two to seven months of treatment with gantenerumab led to dose-dependent amyloid reduction in the brains of patients with Alzheimer's disease", Dr Ostrowitzki said.